Biogen Inc. (BIIB)
 NASDAQ: BIIB · Real-Time Price · USD
 154.27
 +4.66 (3.11%)
  At close: Oct 31, 2025, 4:00 PM EDT
152.77
 -1.50 (-0.97%)
  After-hours: Oct 31, 2025, 5:55 PM EDT
Biogen Revenue
Biogen had revenue of $2.53B in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm) 
 $10.07B
Revenue Growth 
 +4.77%
P/S Ratio 
 2.17
Revenue / Employee 
 $1,323,590
Employees 
 7,605
Market Cap 
22.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% | 
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% | 
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% | 
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% | 
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
BIIB News
- 21 hours ago - Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise - WSJ
- 1 day ago - Biogen trims annual profit forecast on expected hit from R&D-related charges - Reuters
- 4 days ago - Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease - GlobeNewsWire
- 7 days ago - Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion - Reuters
- 7 days ago - Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio - GlobeNewsWire
- 9 days ago - Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 - GlobeNewsWire
- 17 days ago - LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025” - GlobeNewsWire